私募调研勤字当头聚焦“硬科技”“大健康”

Group 1 - In August, private equity firms conducted over 6,000 research activities on A-share companies, reflecting a 200% increase month-on-month, indicating a positive outlook for the market [1] - The pharmaceutical and biotechnology sector became the most favored by private equity firms in August, surpassing the computer sector from July, with 1,095 research activities [1][2] - The electronics, machinery equipment, and power equipment sectors also received significant attention, each with over 400 research activities [1] Group 2 - Leading medical device company Mindray received 117 research activities, making it the most researched A-share company in August [2] - Companies in the electronics sector, such as Crystal Optoelectronics, Feikai Materials, and Anji Technology, saw stock price increases of 33.11%, 23.41%, and 17.24% respectively after receiving intensive research [2] - Smaller private equity firms were particularly active, with Shenzhen Shangcheng Asset leading with 143 research activities [2] Group 3 - Private equity firms focused on "hard technology" and "big health" sectors, emphasizing high elasticity targets and leading companies in niche industries [3] - The surge in research activities in the pharmaceutical and biotechnology sector is attributed to reasonable overall valuations and improved expectations for innovative drug policies and industry fundamentals [3][4] - Research activities were concentrated on companies with core competitiveness and innovation capabilities, indicating a preference for safety margins and certainty in stock selection [4] Group 4 - The recent research trends suggest a high level of interest from private equity firms in sectors like electronics, communications, and computers, which are considered "hard technology" representatives [3][5] - The average position of domestic stock private equity firms was reported at 75.55% as of August 22, indicating a continuous increase in positions over three weeks [5] - Despite fluctuations in the A-share market, private equity firms remain actively engaged in positioning themselves for potential structural investment opportunities [5]